In 2017, at least 2.8 million people in the U.S. acquired serious infections with bacteria that are resistant to one or more antimicrobial drugs and 35,000 have died as a result. Resistance to antimicrobials is viewed as a global threat with antimicrobial drug use in human and animal health driving resistance.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 21 - 30 of 161. 10 per page. Page 3.
Advanced SearchReport
The Inflation Reduction Act of 2022: One Year Anniversary Highlights from ASPE Drug Pricing Reports
Introduction
Fact Sheet
State Fact Sheets: Impacts of the IRA and ACA on Lowering Health Care Costs
Expanding access to high-quality, affordable health care has been a priority of the Biden-Harris Administration.
Report
Inflation Reduction Act Research Series: Medicare Part D Enrollee Out-of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
The Inflation Reduction Act (IRA) will make key changes to improve drug affordability for people who have Medicare.
ASPE Issue Brief
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.
Report to Congress
ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs
Prescription drug shortages are an ongoing concern in the United States (U.S.). While prior analyses explore the frequency of drug shortages in the U.S., little is known about the extent to which U.S. shortages impact consumer costs and healthcare systems. Drug shortages impact consumer costs in various ways.
Report
Understanding Coverage Considerations for COVID-19 Vaccines and Treatments
Understanding Coverage Considerations for COVID-19 Vaccines and Treatments (Updated May 2023)
ASPE Issue Brief
FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits
This issue brief provides a primer on FDA user fees, presents findings of how user fees affect the cost of medical product development, and summarizes the research literature on user fees, most notably in expediting medical product development and approval.
ASPE Issue Brief
Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated enrollee cost-sharing for recommended vaccines covered under Medicare Part D. In 2021, 3.4 million people received vaccines under Part D, and annual out-of-pocket costs were $234 million.
ASPE Data Point
Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics
Effective January 1, 2023, out-of-pocket costs for insulin are capped at $35 per monthly prescription among Medicare Part D enrollees under the Inflation Reduction Act (IRA). A similar cap takes effect in Medicare Part B on July 1, 2023.